Transforming the Future of Hepatology (Part 2A, Breakout Session) : Observational Cohort Development Utilizing Electronic Data to Optimize Cirrhosis Outcomes

Description

This 2-part workshop is dedicated to fostering innovation and collaboration in hepatology research. In part 1, invited talks led by top experts introduce attendees to forward-thinking perspectives on essential research aspects—including cohort design, biomarker development, and clinical trials—providing a rich base for informed conversations. Part 2 deepens the discussions in breakout sessions where experts and junior faculty jointly tackle practical issues of cohort development, biomarker development, and clinical trials. This workshop promises a stimulating environment for attendees to engage in robust discussions and learn from each other with the goal of driving improvements in hepatology research and, ultimately, patient outcomes.

Presentations

3:45 PM - 4:00 PM
Nov 18 2024
San Diego, CA

Strategies to Optimize Cohort Development in Patients With Cirrhosis: Innovative Approaches for Improved Care Coordination, Patient Outcomes, and Research Possibilities

George N. Ioannou, MD, FAASLD, Presenter
Acute Liver Failure
Acute-on-Chronic Liver Failure
ALD
4:00 PM - 4:15 PM
Nov 18 2024
San Diego, CA

Strategies to Optimize Cohort Development in Patients With Cirrhosis: Innovative Approaches for Improved Care Coordination, Patient Outcomes, and Research Possibilities

Giuseppe Cullaro, MD, Presenter
Acute Liver Failure
Acute-on-Chronic Liver Failure
ALD
4:15 PM - 4:30 PM
Nov 18 2024
San Diego, CA

Strategies to Optimize Cohort Development in Patients With Cirrhosis: Innovative Approaches for Improved Care Coordination, Patient Outcomes, and Research Possibilities

Tamar Taddei, MD, MD, FAASLD, Presenter
Acute Liver Failure
Acute-on-Chronic Liver Failure
ALD

Objectives

  • Describe how to build a cohort for clinical research.
  • Identify how to leverage translational research or biomarkers to improve patient clinical outcomes in liver transplantation.
  • Review how to optimize study designs and endpoints, and overcome pitfalls in clinical trial design in portal hypertension.
Chair

Christine C Hsu, MD

National Institute of Health